Advancing Next-Gen ADCs that Target Novel Cancer-Specific Glyco-Targets
Time: 9:10 am
day: Conference Day Two
Details:
- Introducing the O-glycoproteome platform, to expand the druggable target space beyond the proteome
- Discussing how mAbs that recognize clean glycopeptide epitopes mitigate on-target, off-tumor toxicities for higher therapeutic index
- Evidencing ADCs built on glycopeptide-targeting mAbs are less prone to resistance via target down-regulation, and clean tumor selectivity supports the use of more potent payloads